Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health develops, manufactures and markets animal health products for farm animals and pets. News about ELAN commonly covers operating and financial results, product launches in pet health and livestock health, and regulatory actions involving animal medicines and parasite-control products.
Company updates also include capital-structure disclosures, investor conference presentations, and governance changes tied to Elanco's board and public-company operations. Product-specific developments have included the Advantage brand for dogs and emergency-authorized livestock treatments such as Negasunt Powder and Tanidil.
Elanco Animal Health (NYSE: ELAN) has appointed Rajeev (Bobby) Modi as executive vice president of U.S. Pet Health and Global Digital Transformation, effective March 14. Modi has two decades of experience in marketing and sales, previously serving at Conagra Brands and J.M. Smucker, where he led pet portfolio transformation. His role will focus on overseeing veterinary sales, retail, e-commerce, and preparing for upcoming product launches in the pet health pipeline. CEO Jeff Simmons highlighted Modi's expertise and vision for growing Elanco's pet health business.
Elanco Animal Health (NYSE: ELAN) is set to participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022. CEO Jeff Simmons will engage in a virtual fireside chat at 2:50 p.m. ET. Attendees can access a live audio webcast via the "Events and Presentations" section on Elanco's investor website. A replay will be available for 30 days.
TriRx Pharmaceutical Services has completed the acquisition of Elanco Animal Health's manufacturing facility in Speke, UK, finalizing a two-facility sale that includes a site in Shawnee, Kansas. This strategic acquisition enhances TriRx's manufacturing capabilities for both animal and human health products, adding approximately 350 employees and advanced API and biological capacities. TriRx will support Elanco's long-term supply agreement, ensuring reliable product delivery. The acquisition marks a significant step in TriRx's growth strategy as it expands its global presence in the contract development and manufacturing sector.
Summary not available.
Elanco Animal Health (NYSE: ELAN) will participate in the BofA Securities 2022 Virtual Animal Health Summit on February 24, 2022. Jeff Simmons, president and CEO, is scheduled for a virtual fireside chat at 1:35 p.m. ET. A live audio webcast will be accessible in the "Events and Presentations" section of Elanco’s investor website, with a replay available for 30 days.
Elanco Animal Health (NYSE: ELAN) will release its Q4 and full year 2021 financial results on February 24, 2022. A conference call detailing the company’s performance is scheduled for 8:00 a.m. ET that day, accessible via a live webcast on Elanco’s website. The company has a long-standing commitment to enhancing animal health and sustainability through innovative products and services, leveraging nearly 70 years of expertise in the industry.
The FDA has approved Zorbium, a new transdermal solution for managing postoperative pain in cats, marking a significant expansion of Elanco's pain management portfolio. This long-acting medication offers up to four days of postoperative pain control from a single dose, reducing the burden on pet owners for at-home medication administration. Anticipated to launch mid-year 2022, Zorbium underscores Elanco's commitment to innovation in veterinary pain relief, addressing an unmet market need.
Elanco Animal Health (NYSE: ELAN) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. CEO Jeff Simmons is set to present at 10:30 a.m. ET, addressing questions from analysts. A live audio webcast of the event will be accessible on Elanco's investor website, with a replay available for 30 days afterward. Elanco is dedicated to improving animal health with nearly 70 years of experience, focusing on creating value for farmers and pet owners through innovative products and services.
Elanco Animal Health (NYSE: ELAN) announced a significant restructuring plan aimed at simplifying its organization, including eliminating approximately 380 positions, or 20% of senior management, which will incur a fourth quarter charge of $65-$71 million. The company expects this restructuring to generate around $70 million in annual savings, directing resources into high-growth areas, especially in digital capabilities and the Chinese market. Despite the restructuring costs, Elanco maintains its goal of achieving a 60% adjusted gross margin by 2023.
Elanco Animal Health (NYSE: ELAN) will participate in the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021. Jeff Simmons, CEO, will join a virtual fireside chat at 1:50 p.m. ET. A live audio webcast will be available on Elanco’s investor website, with a replay available for 90 days.